Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

被引:821
作者
Levkowitz, G
Waterman, H
Ettenberg, SA
Katz, M
Tsygankov, AY
Alroy, I
Lavi, S
Iwai, K
Reiss, Y
Ciechanover, A
Lipkowitz, S
Yarden, Y
机构
[1] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel
[2] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Ramat Aviv, Israel
[3] Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Biochem, IL-31096 Haifa, Israel
[4] Kyoto Univ, Dept Immunol & Cell Biol, Sankyu Ku, Kyoto 6068501, Japan
[5] Natl Canc Inst, Med Branch, Bethesda, MD 20889 USA
[6] Uniformed Serv Univ Hlth Sci, Mol & Cel Biol Program, Bethesda, MD 20889 USA
[7] Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA
关键词
D O I
10.1016/S1097-2765(00)80231-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Receptor desensitization is accomplished by accelerated endocytosis and degradation of ligand-receptor complexes. An in vitro reconstituted system indicates that Cbl adaptor proteins directly control downregulation of the receptor for the epidermal growth factor (EGFR) by recruiting ubiquitin-activating and -conjugating enzymes. We infer a sequential process initiated by autophosphorylation of EGFR at a previously identified lysosome-targeting motif that subsequently recruits Cbl. This is followed by tyrosine phosphorylation of c-Cbl at a site flanking its RING finger, which enables receptor ubiquitination and degradation. Whereas ail three members of the Cbl family can enhance ubiquitination, two oncogenic Cbl variants, whose RING fingers are defective and phosphorylation sites are missing, are unable to desensitize EGFR. Our study identifies Cbl proteins as components of the ubiquitin ligation machinery and implies that they similarly suppress many other signaling pathways.
引用
收藏
页码:1029 / 1040
页数:12
相关论文
共 44 条
[1]   beta-catenin is a target for the ubiquitin-proteasome pathway [J].
Aberle, H ;
Bauer, A ;
Stappert, J ;
Kispert, A ;
Kemler, R .
EMBO JOURNAL, 1997, 16 (13) :3797-3804
[2]   Degradation of myogenic transcription factor MyoD by the ubiquitin pathway in vivo and in vitro: Regulation by specific DNA binding [J].
Abu Hatoum, O ;
Gross-Mesilaty, S ;
Breitschopf, K ;
Hoffman, A ;
Gonen, H ;
Ciechanover, A ;
Bengal, E .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (10) :5670-5677
[3]   TUMOR-INDUCTION BY ACTIVATED ABL INVOLVES TYROSINE PHOSPHORYLATION OF THE PRODUCT OF THE CBL ONCOGENE [J].
ANDONIOU, CE ;
THIEN, CBF ;
LANGDON, WY .
EMBO JOURNAL, 1994, 13 (19) :4515-4523
[4]   26 S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate [J].
Ben-Shahar, S ;
Komlosh, A ;
Nadav, E ;
Shaked, I ;
Ziv, T ;
Admon, A ;
DeMartino, GN ;
Reiss, Y .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) :21963-21972
[5]   cbl-b inhibits epidermal growth factor receptor signaling [J].
Ettenberg, SA ;
Keane, MM ;
Nau, MM ;
Frankel, M ;
Wang, LM ;
Pierce, JH ;
Lipkowitz, S .
ONCOGENE, 1999, 18 (10) :1855-1866
[6]   KINASE-ACTIVITY CONTROLS THE SORTING OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR WITHIN THE MULTIVESICULAR BODY [J].
FELDER, S ;
MILLER, K ;
MOEHREN, G ;
ULLRICH, A ;
SCHLESSINGER, J ;
HOPKINS, CR .
CELL, 1990, 61 (04) :623-634
[7]   Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells [J].
Feshchenko, EA ;
Langdon, WY ;
Tsygankov, AY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (14) :8323-8331
[8]  
FRENCH AR, 1994, J BIOL CHEM, V269, P15749
[9]  
GalchevaGargova Z, 1995, ONCOGENE, V11, P2649
[10]   Tyrphostins .4. Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines [J].
Gazit, A ;
Chen, J ;
App, H ;
McMahon, G ;
Hirth, P ;
Chen, I ;
Levitzki, A .
BIOORGANIC & MEDICINAL CHEMISTRY, 1996, 4 (08) :1203-1207